307 related articles for article (PubMed ID: 38440738)
1. Overcoming resistance to immune checkpoint blockade in liver cancer - stronger together?
Werner W; Kuzminskaya M; Lurje I; Tacke F; Hammerich L
Semin Liver Dis; 2024 May; ():. PubMed ID: 38806159
[TBL] [Abstract][Full Text] [Related]
2. Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers - how to push the gas after having released the brake.
Rakké YS; Buschow SI; IJzermans JNM; Sprengers D
Front Immunol; 2024; 15():1357333. PubMed ID: 38440738
[TBL] [Abstract][Full Text] [Related]
3. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.
Zhou G; Boor PPC; Bruno MJ; Sprengers D; Kwekkeboom J
Br J Cancer; 2022 Jan; 126(1):10-23. PubMed ID: 34400801
[TBL] [Abstract][Full Text] [Related]
4. Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
Ruff SM; Shannon AH; Pawlik TM
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440
[TBL] [Abstract][Full Text] [Related]
5. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies.
Argemi J; Ponz-Sarvise M; Sangro B
Adv Cancer Res; 2022; 156():367-413. PubMed ID: 35961706
[TBL] [Abstract][Full Text] [Related]
7. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
Oh DY; Ruth He A; Qin S; Chen LT; Okusaka T; Vogel A; Kim JW; Suksombooncharoen T; Ah Lee M; Kitano M; Burris H; Bouattour M; Tanasanvimon S; McNamara MG; Zaucha R; Avallone A; Tan B; Cundom J; Lee CK; Takahashi H; Ikeda M; Chen JS; Wang J; Makowsky M; Rokutanda N; He P; Kurland JF; Cohen G; Valle JW
NEJM Evid; 2022 Aug; 1(8):EVIDoa2200015. PubMed ID: 38319896
[TBL] [Abstract][Full Text] [Related]
9. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Abou-Alfa GK; Lau G; Kudo M; Chan SL; Kelley RK; Furuse J; Sukeepaisarnjaroen W; Kang YK; Van Dao T; De Toni EN; Rimassa L; Breder V; Vasilyev A; Heurgué A; Tam VC; Mody K; Thungappa SC; Ostapenko Y; Yau T; Azevedo S; Varela M; Cheng AL; Qin S; Galle PR; Ali S; Marcovitz M; Makowsky M; He P; Kurland JF; Negro A; Sangro B
NEJM Evid; 2022 Aug; 1(8):EVIDoa2100070. PubMed ID: 38319892
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance.
van Gulijk M; van Krimpen A; Schetters S; Eterman M; van Elsas M; Mankor J; Klaase L; de Bruijn M; van Nimwegen M; van Tienhoven T; van Ijcken W; Boon L; van der Schoot J; Verdoes M; Scheeren F; van der Burg SH; Lambrecht BN; Stadhouders R; Dammeijer F; Aerts J; van Hall T
Sci Immunol; 2023 May; 8(83):eabn6173. PubMed ID: 37205768
[TBL] [Abstract][Full Text] [Related]
11. Combination immunotherapy for hepatocellular carcinoma.
Rimassa L; Finn RS; Sangro B
J Hepatol; 2023 Aug; 79(2):506-515. PubMed ID: 36933770
[TBL] [Abstract][Full Text] [Related]
12. First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
Postel-Vinay S; Lam VK; Ros W; Bauer TM; Hansen AR; Cho DC; Stephen Hodi F; Schellens JHM; Litton JK; Aspeslagh S; Autio KA; Opdam FL; McKean M; Somaiah N; Champiat S; Altan M; Spreafico A; Rahma O; Paul EM; Ahlers CM; Zhou H; Struemper H; Gorman SA; Watmuff M; Yablonski KM; Yanamandra N; Chisamore MJ; Schmidt EV; Hoos A; Marabelle A; Weber JS; Heymach JV
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36927527
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma.
Chavez JC; Foss FM; William BM; Brammer JE; Smith SM; Prica A; Zain JM; Tuscano JM; Shah H; Mehta-Shah N; Geethakumari PR; Wang BX; Zantinge S; Wang L; Zhang L; Boutrin A; Zhao W; Cheng L; Standifer N; Hewitt L; Enowtambong E; Shao W; Sharma S; Carlesso G; Moscow JA; Siu LL
Clin Cancer Res; 2023 May; 29(10):1869-1878. PubMed ID: 36826995
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
